To beat the Covid19 antiviral competition Brilaci
Post# of 72440
(Total Views: 707)
Posted On: 11/07/2020 3:39:32 PM
To beat the Covid19 antiviral competition Brilacidn does not have to have great results {although I pray it does }. It just has to be better than Remdesivir, Regeneron's "neutralizing antibiotic" and convalescent plasma.
The most commonly used drug,Remdesivir, has not been shown to lower mortality, complications or even the viral load.
Regeneron's "neutralizing antibiotic" has shown a reduction in viral load, but no improvement in mortality or reduced complications.In fact last week Regeneron's drug trial was interrupted by poor response and increase in complications in severely ill covid patients.
“It appears a trend is emerging in the class, and it may be that neutralizing antibodies simply do not work and/or are not safe in this (hospitalized) population,” JP Morgan analyst Cory Kasimov said in a note."
His comments are in reference to both Regeneron's and Eli Lilly's Covid 19 drugs.
{From Oct 28,2020} https://investor.regeneron.com/news-releases/...monstrates
{ From Oct30,2020} https://www.reuters.com/article/health-corona...KL4N2HL4IZ
Convalescent plasma has suggested some benefit in a number of trials, but the NIH recently reviewed the data and stated the studies are inconclusive at this time.
{From Oct8 2020} "There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of COVID-19 convalescent plasma for the treatment of COVID-19."
https://www.covid19treatmentguidelines.nih.go...nt-plasma/
It appears the other Covid19 antiviral treatments have floundered and Brilacidin with its terrific in vitro data and pharmacokinetics has an opportunity to be the antiviral of choice against Covid 19 if the human clinical trials confirm its efficacy.
GLTA,Farrell
The most commonly used drug,Remdesivir, has not been shown to lower mortality, complications or even the viral load.
Regeneron's "neutralizing antibiotic" has shown a reduction in viral load, but no improvement in mortality or reduced complications.In fact last week Regeneron's drug trial was interrupted by poor response and increase in complications in severely ill covid patients.
“It appears a trend is emerging in the class, and it may be that neutralizing antibodies simply do not work and/or are not safe in this (hospitalized) population,” JP Morgan analyst Cory Kasimov said in a note."
His comments are in reference to both Regeneron's and Eli Lilly's Covid 19 drugs.
{From Oct 28,2020} https://investor.regeneron.com/news-releases/...monstrates
{ From Oct30,2020} https://www.reuters.com/article/health-corona...KL4N2HL4IZ
Convalescent plasma has suggested some benefit in a number of trials, but the NIH recently reviewed the data and stated the studies are inconclusive at this time.
{From Oct8 2020} "There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of COVID-19 convalescent plasma for the treatment of COVID-19."
https://www.covid19treatmentguidelines.nih.go...nt-plasma/
It appears the other Covid19 antiviral treatments have floundered and Brilacidin with its terrific in vitro data and pharmacokinetics has an opportunity to be the antiviral of choice against Covid 19 if the human clinical trials confirm its efficacy.
GLTA,Farrell
(10)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼